NEW
YORK, June 24, 2024 /PRNewswire/ -- ANEW
MEDICAL, INC. ("ANEW" or the "Company") announces the Company's
common shares and warrants will begin trading on the NASDAQ Global
Market under the ticker symbols "WENA" and "WENAW",
respectively.
ANEW is a specialty pharmaceutical company specializing in the
advancement of diagnostics and novel disease-modifying therapies
for neurological and age-related disorders.
Dr. Joseph Sinkule, Founder and
CEO of ANEW, commented, "Today marks our first day as a publicly
traded company and as a dedicated leader in the development of
novel disease-modifying therapies for neurological and age-related
disorders. We're a relatively new company but our management team
has a long legacy of developing therapies to improve the quality of
life globally. We are excited to update the market on the
development of several platform technologies and product candidates
we have licensed and plan to announce several key milestones we
have accomplished over the past year."
Dr. Sinkule, concluded: "ANEW is well-positioned to create
long-term value for shareholders through a greater focus on our
core business. Through this transaction, we will make advancements
to execute on industry-specific growth and market strategies with a
focus on strategic capital allocation strategies."
On June 21, 2024, Redwoods
Acquisition Corp. (NASDAQ:RWOD) ("RWOD"), a publicly-traded
special purpose acquisition company, announced the completion of
their previously announced business combination with ANEW MEDICAL,
INC. Today, June 24, 2024, the
Company is trading under the "WENA" symbol.
About ANEW MEDICAL, INC.
ANEW specializes in the development of diagnostics and novel
disease-modifying therapies for neurological and age-related
disorders. The company's focus on central nervous systems (CNS)
diseases utilizing cell and gene therapies to mitigate age-related
pathologies such as Alzheimer's disease, dementia symptoms and
neuromuscular diseases. The Company has exclusive worldwide rights
to develop and commercialize proprietary product platforms based on
its proprietary isoform transcribed from the human Klotho gene
referred to as secreted Klotho or "s-KL". This s-KL protein or gene
therapy has been recognized for its potential to mitigate
age-related pathologies such as ALS, Alzheimer's and Parkinson's
Disease. The Company is also evaluating other core technology
platforms to acquire for development and commercialization by the
Company.
For further information:
Contact Investor Relations
Email: ir@anewmeds.com
Telephone: (833)-931-6330
Website: www.anewmeds.com
Forward-Looking Statements - This press release
contains forward-looking statements. All statements other than
statements of historical facts are "forward-looking statements,"
including those relating to future events. In some cases,
forward-looking statements can be identified by terminology such as
"plan", "expect", "anticipate", "may", "might", "will", "should",
"project", "believe", "estimate", "predict", "potential", "intend",
or "continue", or other words or terms of similar meaning. These
statements include, without limitation, statements related to
research, pre-clinical data, plans for future development, and the
potential of a drug development candidate. These forward-looking
statements are based on our current plans, objectives, estimates,
expectations and intentions, and inherently involve significant
risks and uncertainties. Actual results and the timing of events
could differ materially from those anticipated in such
forward-looking statements as a results of these risks and
uncertainties, which include, without limitation, risks and
uncertainties with the COVID-19 pandemic and its impact on the
Company's clinical plans and business strategy, risks and
uncertainties associated with product development and clinical
success thereof, the uncertainties of regulatory approvals, and
manufacturing and supply risks, other risks and uncertainties
affecting the Company and its research and development programs as
set forth in its SEC filings. Other risks and uncertainties of
which the Company is not currently aware may also affect the
Company's forward-looking statements and may cause actual results
and the timing of events to differ materially from those
anticipated. The forward-looking statements herein are made only as
of the date hereof. The Company undertakes no obligation to update
or supplement any forward-looking statements to reflect actual
results, new information, future events, changes in its
expectations or other circumstances that exist after the date as of
which the forward-looking statements were made.
View original
content:https://www.prnewswire.com/news-releases/anew-medical-inc-commences-trading-on-nasdaq-under-ticker-symbol-wena-302180419.html
SOURCE ANEW MEDICAL, INC.